Market Cap
US$67.1m
Last Updated
2019/07/17 00:47 UTC
Data Sources
Company Financials +
Executive Summary
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States.
Snowflake
Fundamentals
High growth potential with excellent balance sheet.
Risks
- SCYNEXIS has significant price volatility in the past 3 months.
Share Price & News
How has SCYNEXIS's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-3.1%
NasdaqGM:SCYX
-3.8%
US Pharmaceuticals
0.6%
US Market
1 Year Return
-32.8%
NasdaqGM:SCYX
3.4%
US Pharmaceuticals
4.1%
US Market
SCYX underperformed the Pharmaceuticals industry which returned 5% over the past year.
SCYX underperformed the Market in United States of America which returned 4.7% over the past year.
Share holder returns
| SCYX | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.1% | -3.8% | 0.6% |
| 30 Day | -4.6% | -1.0% | 3.8% |
| 90 Day | -24.2% | 1.0% | 2.8% |
| 1 Year | -32.8%-32.8% | 5.8%3.4% | 6.4%4.1% |
| 3 Year | -39.6%-39.6% | 9.2%1.5% | 47.0%37.3% |
| 5 Year | -82.5%-82.5% | 26.2%12.6% | 60.3%42.5% |
Price Volatility Vs. Market
How volatile is SCYNEXIS's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Could The SCYNEXIS, Inc. (NASDAQ:SCYX) Ownership Structure Tell Us Something Useful?5 months ago | Simply Wall St
SCYNEXIS, Inc. (NASDAQ:SCYX): What Does Its Beta Value Mean For Your Portfolio?6 months ago | Simply Wall St
Could SCYNEXIS, Inc.'s (NASDAQ:SCYX) Investor Composition Influence The Stock Price?Valuation
Is SCYNEXIS undervalued based on future cash flows and its price relative to the stock market?
5.54x
Price to Book (PB) ratio
Intrinsic Value Based on Future Cash Flows
Unable to calculate intrinsic value for SCYNEXIS to establish if it is available at moderate discount.
Unable to calculate intrinsic value for SCYNEXIS to establish if it is available at substantial discount.
Price Based on Earnings
SCYNEXIS is loss making, we can't compare its value to the US Pharmaceuticals industry average.
SCYNEXIS is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for SCYNEXIS, we can't assess if its growth is good value.
Price Based on Value of Assets
SCYNEXIS is overvalued based on assets compared to the US Pharmaceuticals industry average.
Next Steps
Future Growth
How is SCYNEXIS expected to perform in the next 1 to 3 years based on estimates from 5 analysts?
47.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
SCYNEXIS's revenue is expected to grow significantly at over 20% yearly.
SCYNEXIS's earnings are expected to grow significantly at over 20% yearly.
SCYNEXIS's revenue growth is expected to exceed the United States of America market average.
SCYNEXIS's earnings growth is expected to exceed the United States of America market average.
SCYNEXIS's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if SCYNEXIS will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has SCYNEXIS performed over the past 5 years?
6.6%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
SCYNEXIS does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
Unable to compare SCYNEXIS's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare SCYNEXIS's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if SCYNEXIS has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if SCYNEXIS has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if SCYNEXIS improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is SCYNEXIS's financial position?
Financial Position Analysis
SCYNEXIS is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
SCYNEXIS's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
SCYNEXIS's level of debt (74.6%) compared to net worth is high (greater than 40%).
SCYNEXIS had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
Balance Sheet
Low level of unsold assets.
Debt is covered by short term assets, assets are 4.7x debt.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
SCYNEXIS has sufficient cash runway for 1.4 years based on current free cash flow.
SCYNEXIS has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of -3.2% each year.
Next Steps
Dividend
What is SCYNEXIS's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate SCYNEXIS's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate SCYNEXIS's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as SCYNEXIS has not reported any payouts.
Unable to verify if SCYNEXIS's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as SCYNEXIS has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of SCYNEXIS's salary, the management and board of directors tenure and is there insider trading?
3.9yrs
Average management tenure
CEO
Marco Taglietti (59yo)
4.3yrs
Tenure
US$1,114,895
Compensation
Dr. Marco Taglietti, M.D. has been the Chief Executive Officer of SCYNEXIS, Inc. since April 1, 2015 and has been President since September 24, 2015. Dr. Taglietti served as Senior Vice President, Head of ...
CEO Compensation Analysis
Marco's remuneration is higher than average for companies of similar size in United States of America.
Marco's compensation has been consistent with company performance over the past year, both up more than 20%.
Management Age and Tenure
3.9yrs
Average Tenure
49yo
Average Age
The tenure for the SCYNEXIS management team is about average.
Board Age and Tenure
4.3yrs
Average Tenure
60.5yo
Average Age
The tenure for the SCYNEXIS board of directors is about average.
Insider Trading
No 3 month individual insider trading information.
Recent Insider Transactions
| Entity | Individual |
| Role | CEO, President & Director Member of the Board of Directors |
| Shares | 25,000 |
| Max Price | US$1.63 |
| Entity | Individual |
| Role | CEO, President & Director Member of the Board of Directors |
| Shares | 25,000 |
| Max Price | US$0.69 |
| Entity | Individual |
| Role | CEO, President & Director Member of the Board of Directors |
| Shares | 25,000 |
| Max Price | US$0.46 |
| Entity | Individual |
| Role | Chief Medical Officer |
| Shares | 12,000 |
| Max Price | US$0.50 |
| Entity | Individual |
| Role | Chief Medical Officer |
| Shares | 7,000 |
| Max Price | US$1.27 |
| Entity | Individual |
| Role | CEO, President & Director Member of the Board of Directors |
| Shares | 25,000 |
| Max Price | US$1.29 |
Ownership Breakdown
Management Team
Marco Taglietti (59yo)
CEO, President & Director
- Tenure: 4.3yrs
- Compensation: $1.11m
David Angulo (54yo)
Chief Medical Officer
- Tenure: 4.1yrs
- Compensation: $768.61k
Eric Francois (44yo)
Chief Financial Officer
- Tenure: 3.7yrs
- Compensation: $664.70k
Scott Sukenick (41yo)
General Counsel & Corporate Secretary
- Tenure: 1.7yrs
Board Members
Armando Anido (61yo)
Director
- Tenure: 0.5yrs
Dave Hastings (58yo)
Independent Director
- Tenure: 3.8yrs
- Compensation: $72.75k
Ann Hanham (66yo)
Independent Director
- Tenure: 10.6yrs
- Compensation: $72.75k
Guy MacDonald (60yo)
Chairman of the Board
- Tenure: 4.1yrs
- Compensation: $81.83k
Steve Gilman (66yo)
Independent Director
- Tenure: 4.4yrs
- Compensation: $69.00k
Marco Taglietti (59yo)
CEO, President & Director
- Tenure: 4.7yrs
- Compensation: $1.11m
Company Information
SCYNEXIS, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: SCYNEXIS, Inc.
- Ticker: SCYX
- Exchange: NasdaqGM
- Founded: 1999
- Industry: pharmaceuticals
- Sector: pharmaceuticals & biotech
- Market Cap: US$67.064m
- Shares outstanding: 53.65m
- Website: Click here
Number of Employees
Location
- SCYNEXIS, Inc.
- 1 Evertrust Plaza
- 13th Floor
- Jersey City
- New Jersey
- 7302
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SCYX | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | May 2014 |
| 135 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | May 2014 |
Biography
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intrave ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/07/17 00:47 |
| End of Day Share Price | 2019/07/16 00:00 |
| Earnings | 2019/03/31 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.